Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
(4) - EconoTimes)
SANTA BARBARA, Calif., March 11, 2016 -- Sientra, Inc. (NASDAQ:SIEN) (“Sientra”), a medical aesthetics company, today announced that it has granted a nonstatutory stock option under its Inducement Plan for 30,000 shares of Sientra common stock to Douglas M. Goodner, Sientra’s new Director of Strategic Programs pursuant to the terms of his employment agreement with Sientra. This award was approved by the Compensation Committee of Sientra’s board of directors and was granted as an inducement material to Mr. Goodner’s entering into employment with Sientra, pursuant to Rule 5635(b)(4) of the NASDAQ Listing Rules.
Mr. Goodner’s stock option was granted effective March 8, 2016 and has a ten year term and an exercise price equal to $7.93 per share, which was the closing trading price of Sientra’s common stock on the NASDAQ Global Select Market on the date of grant. Such stock option vests over the course of four years, with 25% of the shares subject to the option vesting on the one-year anniversary of the grant date and 1/48 of the shares subject to the option vesting monthly thereafter, subject to the new employee's continued service relationship with Sientra on each vesting date.
About Sientra
Headquartered in Santa Barbara, California, Sientra is a medical aesthetics company committed to making a difference in patients' lives by enhancing their body image, growing their self-esteem and restoring their confidence. The Company was founded to provide greater choice to board-certified plastic surgeons and patients in need of medical aesthetics products. The Company has developed a broad portfolio of products with technologically differentiated characteristics, supported by independent laboratory testing and strong clinical trial outcomes. The Company sells its breast implants and breast tissue expanders exclusively to board-certified and board-admissible plastic surgeons and tailors its customer service offerings to their specific needs. The Company also offers a range of other aesthetic and specialty products.
Contact Investor Contact: The Ruth Group Nick Laudico / Brandon Vazquez (646) 536-7030 / 7032 [email protected]
